Roche pays $55M upfront for Zymeworks T-cell engager
Roche agreed to pay Zymeworks $55 million upfront for global rights to a preclinical trispecific T-cell engager. The total deal value could reach $813 million, and the therapy is positioned as a potential rival to Amgen's Imdelltra.
Roche has committed $55 million as an initial payment to Zymeworks for rights covering the world to a trispecific T-cell engager still in preclinical work. The deal’s overall worth may climb to $813 million.
The candidate is positioned as a possible challenger to Amgen’s Imdelltra. Since it remains preclinical, the agreement centers on early-stage partnering rather than a therapy already in clinical testing.
If the therapy advances, patients who rely on T-cell engagers could gain another treatment option, and competition with existing products may influence pricing or access. Zymeworks could benefit from the larger potential deal value, while investors may view the agreement as validation of early-stage biotech assets. Because the therapy is preclinical, however, any broad societal benefit may be years away and remains uncertain.